Top

Published in:

01-06-2021 | Ovarian Cancer | Special Section: Ovarian Cancer

Current update on the molecular genetics and management of hereditary ovarian cancers: a primer for radiologists

Authors: Malak Itani, Neeraj Lalwani, Dhakshinamoorthy Ganeshan, Maria Zulfiqar, Cary Siegel

Published in: Abdominal Radiology | Issue 6/2021

Abstract

More than one-fifth of ovarian cancers are hereditary, with most of them caused by BRCA genes. Malignant ovarian neoplasms are primarily epithelial tumors, a heterogeneous group of tumors with variable genetic backgrounds that translate into different biologic behaviors and morphologic features. Radiologists play an increasingly important role in the diagnosis and management of oncology patients. Familiarity with hereditary ovarian cancers will have a positive impact on patient management and radiologists’ involvement in the multidisciplinary approach needed for this delicate patient population. In this paper, we review the basic histologic and genetic backgrounds of ovarian tumors with an emphasis on hereditary ovarian cancers, as well as the effects that these factors have on patient workup, primarily with regard to imaging studies.

Doubeni CA, Doubeni AR, Myers AE (2016) Diagnosis and Management of Ovarian Cancer. Am Fam Physician 93 (11):937-944PubMed

SEER Cancer Statistics Review, 1975–2017, based on November 2019 SEER data submission. National Cancer Institute. https://seer.cancer.gov/csr/1975_2017/. Accessed 6/27/2020

Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L (2015) Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int 2015:341723. https://doi.org/10.1155/2015/341723CrossRefPubMedPubMedCentral

Kasprzak L, Foulkes WD, Shelling AN (1999) Forth nightly review: hereditary ovarian carcinoma. BMJ 318 (7186):786-789. https://doi.org/10.1136/bmj.318.7186.786CrossRefPubMedPubMedCentral

Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, Franklin G, Ngozi A, Cantuaria G, Singh K, Grizzle W, Landen C, Partridge EE, Rice VM, Reddy ES, Rao VN (2014) Epithelial ovarian cancer: An overview. World J Transl Med 3 (1):1-8. https://doi.org/10.5528/wjtm.v3.i1.1CrossRefPubMedPubMedCentral

Low JJ, Ilancheran A, Ng JS (2012) Malignant ovarian germ-cell tumours. Best Pract Res Clin Obstet Gynaecol 26 (3):347-355. https://doi.org/10.1016/j.bpobgyn.2012.01.002CrossRefPubMed

Jung SE, Rha SE, Lee JM, Park SY, Oh SN, Cho KS, Lee EJ, Byun JY, Hahn ST (2005) CT and MRI findings of sex cord-stromal tumor of the ovary. AJR Am J Roentgenol 185 (1):207-215. https://doi.org/10.2214/ajr.185.1.01850207CrossRefPubMed

Kurman RJ (2013) Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 24 Suppl 10:x16-21. https://doi.org/10.1093/annonc/mdt463CrossRefPubMed

Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34 (3):433-443. https://doi.org/10.1097/PAS.0b013e3181cf3d79CrossRefPubMedPubMedCentral

10.

Weinberger V, Minar L, Felsinger M, Ovesna P, Bednarikova M, Cihalova M, Jandakova E, Hausnerova J, Chaloupkova B, Zikan M (2018) Brenner tumor of the ovary - ultrasound features and clinical management of a rare ovarian tumor mimicking ovarian cancer. Ginekol Pol 89 (7):357-363. https://doi.org/10.5603/GP.a2018.0061CrossRefPubMed

11.

Koshiyama M, Matsumura N, Konishi I (2014) Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int 2014:934261. https://doi.org/10.1155/2014/934261CrossRefPubMedPubMedCentral

12.

Dubeau L (2008) The cell of origin of ovarian epithelial tumours. Lancet Oncol 9 (12):1191-1197. https://doi.org/10.1016/S1470-2045(08)70308-5CrossRefPubMedPubMedCentral

13.

Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST (2002) CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 22 (6):1305-1325. https://doi.org/10.1148/rg.226025033CrossRefPubMed

14.

Boussios S, Mikropoulos C, Samartzis E, Karihtala P, Moschetta M, Sheriff M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N (2020) Wise Management of Ovarian Cancer: On the Cutting Edge. J Pers Med 10 (2). https://doi.org/10.3390/jpm10020041

15.

Hollis RL, Gourley C (2016) Genetic and molecular changes in ovarian cancer. Cancer Biol Med 13 (2):236-247. https://doi.org/10.20892/j.issn.2095-3941.2016.0024CrossRefPubMedPubMedCentral

16.

Lim D, Oliva E (2013) Precursors and pathogenesis of ovarian carcinoma. Pathology 45 (3):229-242. https://doi.org/10.1097/PAT.0b013e32835f2264CrossRefPubMed

17.

Manchana T, Phoolcharoen N, Tantbirojn P (2019) BRCA mutation in high grade epithelial ovarian cancers. Gynecol Oncol Rep 29:102-105. https://doi.org/10.1016/j.gore.2019.07.007CrossRefPubMedPubMedCentral

18.

George SH, Shaw P (2014) BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol 4:5. https://doi.org/10.3389/fonc.2014.00005CrossRefPubMedPubMedCentral

19.

Kobayashi H, Ohno S, Sasaki Y, Matsuura M (2013) Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep 30 (3):1019-1029. https://doi.org/10.3892/or.2013.2541CrossRefPubMed

20.

Williams SA, Wilson JB, Clark AP, Mitson-Salazar A, Tomashevski A, Ananth S, Glazer PM, Semmes OJ, Bale AE, Jones NJ, Kupfer GM (2011) Functional and physical interaction between the mismatch repair and FA-BRCA pathways. Hum Mol Genet 20 (22):4395-4410. https://doi.org/10.1093/hmg/ddr366CrossRefPubMedPubMedCentral

21.

Neff RT, Senter L, Salani R (2017) BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 9 (8):519-531. https://doi.org/10.1177/1758834017714993CrossRefPubMedPubMedCentral

22.

Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, Powell A, Manti L, McDade SS, Park BH, Prise KM, McIntosh SA, Salto-Tellez M, Richard DJ, Elliott CT, Harkin DP (2014) BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Res 74 (10):2773-2784. https://doi.org/10.1158/0008-5472.CAN-13-2611CrossRefPubMedPubMedCentral

23.

Hamada J, Nakata D, Nakae D, Kobayashi Y, Akai H, Konishi Y, Okada F, Shibata T, Hosokawa M, Moriuchi T (2001) Increased oxidative DNA damage in mammary tumor cells by continuous epidermal growth factor stimulation. J Natl Cancer Inst 93 (3):214-219. https://doi.org/10.1093/jnci/93.3.214CrossRefPubMed

24.

Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 31 (33):4188-4198. https://doi.org/10.1200/JCO.2013.48.9021CrossRefPubMed

25.

Faraoni I, Graziani G (2018) Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers (Basel) 10 (12). https://doi.org/10.3390/cancers10120487

26.

Jang E, Chung DC (2010) Hereditary colon cancer: lynch syndrome. Gut Liver 4 (2):151-160. https://doi.org/10.5009/gnl.2010.4.2.151CrossRefPubMedPubMedCentral

27.

Nakamura K, Banno K, Yanokura M, Iida M, Adachi M, Masuda K, Ueki A, Kobayashi Y, Nomura H, Hirasawa A, Tominaga E, Aoki D (2014) Features of ovarian cancer in Lynch syndrome (Review). Mol Clin Oncol 2 (6):909-916. https://doi.org/10.3892/mco.2014.397CrossRefPubMedPubMedCentral

28.

Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK (2009) Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3 (2):97-137. https://doi.org/10.1016/j.molonc.2009.02.004CrossRefPubMedPubMedCentral

29.

Helder-Woolderink JM, Blok EA, Vasen HF, Hollema H, Mourits MJ, De Bock GH (2016) Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer 55:65-73. https://doi.org/10.1016/j.ejca.2015.12.005CrossRefPubMed

30.

Ryan NAJ, Evans DG, Green K, Crosbie EJ (2017) Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. Gynecol Oncol 144 (3):491-495. https://doi.org/10.1016/j.ygyno.2017.01.005CrossRefPubMedPubMedCentral

31.

Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM (2006) Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6:201. https://doi.org/10.1186/1471-2407-6-201CrossRefPubMedPubMedCentral

32.

Tuna M, Ju Z, Yoshihara K, Amos CI, Tanyi JL, Mills GB (2020) Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. Br J Cancer 122 (3):405-412. https://doi.org/10.1038/s41416-019-0654-8CrossRefPubMed

33.

Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 108 (44):18032-18037. https://doi.org/10.1073/pnas.1115052108CrossRefPubMedPubMedCentral

34.

Schultz KA, Harris A, Messinger Y, Sencer S, Baldinger S, Dehner LP, Hill DA (2016) Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry. Fam Cancer 15 (1):105-110. https://doi.org/10.1007/s10689-015-9831-yCrossRefPubMedPubMedCentral

35.

Pirschner F, Bastos PM, Contarato GL, Bimbato AC, Filho AC (2012) Gorlin syndrome and bilateral ovarian fibroma. Int J Surg Case Rep 3 (9):477-480. https://doi.org/10.1016/j.ijscr.2012.05.015CrossRefPubMedPubMedCentral

36.

Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, Bale AE, Bale SJ (1997) Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 69 (3):299-308CrossRef

37.

Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, Hirasawa A, Aoki D (2013) Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review). Oncol Lett 6 (5):1184-1188. https://doi.org/10.3892/ol.2013.1527CrossRefPubMedPubMedCentral

38.

Matsubayashi H, Higashigawa S, Kiyozumi Y, Horiuchi Y, Hirashima Y, Kado N, Abe M, Ohishi T, Ohnami S, Urakami K, Yamaguchi K (2019) Metachronous ovarian endometrioid carcinomas in a patient with a PTEN variant: case report of incidentally detected Cowden syndrome. BMC Cancer 19 (1):1014. https://doi.org/10.1186/s12885-019-6272-2CrossRefPubMedPubMedCentral

39.

Yauy K, Imbert-Bouteille M, Bubien V, Lindet-Bourgeois C, Rathat G, Perrochia H, MacGrogan G, Longy M, Bessis D, Tinat J, Baert-Desurmont S, Blanluet M, Perre PV, Baudry K, Pujol P, Corsini C (2019) Ovarian Clear Cell Carcinoma in Cowden Syndrome. J Natl Compr Canc Netw 17 (1):7-11. https://doi.org/10.6004/jnccn.2018.7065CrossRefPubMed

40.

Gammon A, Jasperson K, Champine M (2016) Genetic basis of Cowden syndrome and its implications for clinical practice and risk management. Appl Clin Genet 9:83-92. https://doi.org/10.2147/TACG.S41947CrossRefPubMedPubMedCentral

41.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2020 www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

42.

Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group ACoMG, Genomics Professional P, Guidelines C, National Society of Genetic Counselors Practice Guidelines C (2015) A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 17 (1):70-87. https://doi.org/10.1038/gim.2014.147CrossRef

43.

This P, de la Rochefordiere A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D, Institut Curie B, Ovarian Cancer Risk Study G (2012) Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome. Fam Cancer 11 (3):473-482. https://doi.org/10.1007/s10689-012-9539-1CrossRef

44.

Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB (2014) Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 14:150. https://doi.org/10.1186/s12905-014-0150-5CrossRefPubMedPubMedCentral

45.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K (2002) Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8 (12):3776-3781PubMed

46.

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD, Team PP (2011) Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305 (22):2295-2303. https://doi.org/10.1001/jama.2011.766CrossRef

47.

Kamal R, Hamed S, Mansour S, Mounir Y, Abdel Sallam S (2018) Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality. Br J Radiol 91 (1090):20170571. https://doi.org/10.1259/bjr.20170571CrossRefPubMedPubMedCentral

48.

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ (2016) Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387 (10022):945-956. https://doi.org/10.1016/S0140-6736(15)01224-6CrossRefPubMedPubMedCentral

49.

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR (2007) Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109 (2):221-227. https://doi.org/10.1002/cncr.22371CrossRef

50.

Chung SH, Lee SY, Ju W, Kim SC (2013) Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study. Obstet Gynecol Sci 56 (4):234-241. https://doi.org/10.5468/ogs.2013.56.4.234CrossRefPubMedPubMedCentral

51.

Yabuuchi H, Matsuo Y, Sunami S, Kamitani T, Kawanami S, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Tokunaga E, Yamamoto H, Honda H (2011) Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging. Eur Radiol 21 (1):11-17. https://doi.org/10.1007/s00330-010-1890-8CrossRefPubMed

52.

Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 107 (1):24-30. https://doi.org/10.1038/bjc.2012.204CrossRefPubMedPubMedCentral

53.

Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29 (13):1664-1669. https://doi.org/10.1200/jco.2009.27.0835CrossRefPubMedPubMedCentral

54.

Elezaby M, Lees B, Maturen KE, Barroilhet L, Wisinski KB, Schrager S, Wilke LG, Sadowski E (2019) BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations. Radiology 291 (3):554-569. https://doi.org/10.1148/radiol.2019181814CrossRefPubMed

55.

Andreotti RF, Timmerman D, Strachowski LM, Froyman W, Benacerraf BR, Bennett GL, Bourne T, Brown DL, Coleman BG, Frates MC, Goldstein SR, Hamper UM, Horrow MM, Hernanz-Schulman M, Reinhold C, Rose SL, Whitcomb BP, Wolfman WL, Glanc P (2020) O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. Radiology 294 (1):168-185. https://doi.org/10.1148/radiol.2019191150CrossRefPubMed

56.

Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO (2017) BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. Radiographics 37 (4):1005-1023. https://doi.org/10.1148/rg.2017160144CrossRefPubMed

57.

Nandy S, Mostafa A, Hagemann IS, Powell MA, Amidi E, Robinson K, Mutch DG, Siegel C, Zhu Q (2018) Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US. Radiology 289 (3):740-747. https://doi.org/10.1148/radiol.2018180666CrossRefPubMedPubMedCentral

58.

Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177 (3):1053-1064. https://doi.org/10.2353/ajpath.2010.100105CrossRefPubMedPubMedCentral

59.

Nougaret S, Lakhman Y, Gonen M, Goldman DA, Micco M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E (2017) High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. Radiology 285 (2):472-481. https://doi.org/10.1148/radiol.2017161697CrossRefPubMedPubMedCentral

Title: Current update on the molecular genetics and management of hereditary ovarian cancers: a primer for radiologists
Authors: Malak Itani
Neeraj Lalwani
Dhakshinamoorthy Ganeshan
Maria Zulfiqar
Cary Siegel
Publication date: 01-06-2021
Publisher: Springer US
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Abdominal Radiology / Issue 6/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-020-02911-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Current update on the molecular genetics and management of hereditary ovarian cancers: a primer for radiologists

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

Ultrasound features help identify patients who can undergo noninvasive management for suspected retained products of conception: a single institutional experience

Imaging of abdominal and pelvic infections in the cancer patient

Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma—a literature review

Radiomics and radiogenomics in ovarian cancer: a literature review

Evaluation of clinical and imaging biomarkers for the prediction of new onset diabetes following pancreatic resection

Current update on malignant epithelial ovarian tumors

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page